New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
14:27 EDTVRXJublia could become Valeant's biggest product, says Jefferies
After Valeant announced FDA approval for Jublia, on schedule and as expected, Jefferies said the product targets an underserved market and could become the company's biggest drug. Jefferies sees peak worldwide sales for Jublia of $400M-$500M, but adds that its forecast could be conservative. The firm maintains its Buy rating and $154 price target on Valeant.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use